Optometry

As a rule, the latest and greatest new technology first becomes available to the haves in this world, and only much later, if at all, to the have-nots.

Adoption of electronic health record technology has been slow, particularly among ophthalmologists.

Many agents have been investigated in clinical trials for neuroprotection in glaucoma, but none has proven efficacy, and so IOP control continues to be the mainstay strategy for preventing glaucoma progression.

Epimacular brachytherapy was described as "interesting and encouraging" at the 2-year time point for treating exudative age-related macular degeneration that had been previously treated with anti-vascular endothelial growth factor injections.

Topical branded nonsteroidal anti-inflammatory drugs are safe to use in patients with evaporative dry eye syndrome and in those with meibomian gland dysfunction.

Results from randomized controlled clinical trials investigating populations covering the spectrum from ocular hypertension to advanced glaucoma provide clear evidence that for most patients, glaucoma is an IOP-sensitive optic neuropathy for which lowering IOP is effective in slowing or arresting progression.

Ophthalmologists should not order routine genetic tests for patients with common disorders like age-related macular degeneration until there are specific therapeutic interventions available to treat the disease based on the genetic information.

The acceleration of research focused on dry eye over the past several decades has led to an increase in knowledge regarding the pathophysiology of the disease.

Dry eye comes in a variety of guises and, once diagnosed, may require various therapeutic options.

The world of glaucoma management in 2012 is feeling the impact of not only a variety of challenges, but also new opportunities.

Many ophthalmologists may be dropping the ball when treating moderate dry eye, which could result in progression to more severe stages of disease.

Having the ARVO meeting in any of various locations enables the group to accommodate more program options and have a variety of hotel options nearby.

FDA investigators say counterfeit vials of Roche/Genentech's bevacizumab that have turned up in U.S. medical practices for the second time in 2 months have no active ingredient.

Tear osmolarity is well correlated to visual function, and may also be a key marker of dry eye disease

Ophthalmologists expressed a little more optimism than primary-care physicians, when asked to evaluate the financial state of their practices in a national survey conducted in 2011.

The golden rule, a maxim the author learned in kindergarten, remains crucial to his practice of medicine today.

It is vital to identify and prevent dry eye and blepharitis pre-surgery because these conditions can affect IOL calculations and more.

The tear layer approach is effective in the diagnosis and treatment of dry eye syndrome.

Though advances have been made in achieving better functional vision in some patients with ocular injuries, the overall rates of improvements in visual acuity have remained static for three decades.

In this quartery column in association with Ophthalmic Women Leaders, Beiting launches the series with five pearls for anyone seeking more exposure from the podium.

Paul P. Lee, MD, JD, has come full circle. After earning his undergraduate and medical degrees from the University of Michigan in the 1980s, Dr. Lee has returned as chairman of the Department of Ophthalmology and Visual Sciences and holder of the F. Bruce Fralick scholarship.

Optimizing outcomes with correct IOL calculations for combined Descemet's stripping automated endothelial keratoplasty, cataract extraction, and IOL implantation procedures can be achieved with the same techniques that are used in cataract surgery.

Ophthalmology Times was honored for Best News Coverage at the 58th annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence.

The FDA clearance this past February for a second-generation version of a proprietary device allows physicians to treat both eyes simultaneously for meibomian gland dysfunction and evaporative dry eye in a relatively painless in-office procedure.

Integrin peptide therapy is an emerging new class of treatment for neovascular eye diseases, such as wet age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion.

Many ophthalmologists have yet to embrace the role of "refractive" cataract surgeon by offering premium refractive IOLs to their patients.

Novel strategies have been developed to track the progression of dry age-related macular degeneration by monitoring the change in geographic atrophy and drusen using spectral-domain optical coherence tomography.

The FDA has granted IDE approval to Ocular Therapeutix to conduct a pivotal clinical trial investigating its proprietary synthetic ocular hydrogel polymer bandage for covering clear corneal incisions after cataract surgery.

The author describes a stepwise approach to assessing and addressing the ocular surface to enhance outcomes with cataract surgery.

Results from patients treated for refractory ulcers due to infectious keratitis show corneal collagen crosslinking is an effective intervention that results in rapid and complete healing.